3d metal complexes with meloxicam as therapeutic agents in the fight against human glioblastoma multiforme and cervical carcinoma

References

• Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterol. 2001;120:594–606.
   PubMed Web of Science ®Google Scholar
• Díaz-Rodríguez L, García-Martínez O, Morales MA, et al. Effects of indomethacin, nimesulide, and diclofenac on human MG-63 osteosarcoma cell line. Biol Res Nurs. 2012;14(1):98–107.
   PubMed Web of Science ®Google Scholar
• Zochling J, Van Der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65:423–432.
   PubMed Web of Science ®Google Scholar
• Karateev AE, Erdes ShF. Use of nonsteroidal anti-inflammatory drugs in case of ankylosing spondylitis: long and persistently!. Ter Arkh. 2014;86(11):123–127. (in Russian)
   PubMed Web of Science ®Google Scholar
• Van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;9:CD010120.
   PubMed Web of Science ®Google Scholar
• Becker DE. Pain management: Part 1: Managing acute and postoperative dental pain. Anesth Prog. 2010;57(2):67–78.
   PubMedGoogle Scholar
• Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother. 2014;15(13):1863–1874.
   PubMed Web of Science ®Google Scholar
• Connolly TP. Cyclooxygenase-2 inhibitors in gynecologic practice. Clin Med Res. 2003;1:105–110.
   PubMedGoogle Scholar
• Tablov B, Tablov V, Popov I. Modern aspects of perioperative analgesia by using nonsteroidal anti-inflammatory drugs in gynecology (Part I). Akush Ginekol (Sofia). 2006;45(1):41–44. (in Bulgarian)
   PubMedGoogle Scholar
• Fosslien E. Molecular pathology of cyclooxygenase 2 in neoplasia. Ann Clin Lab Sci. 2000;30:3–21.
   PubMed Web of Science ®Google Scholar
• Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res Clin Oncol. 2001;127:411–417.
   PubMed Web of Science ®Google Scholar
• Khan MN, Lee YS. Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy. Med Res Rev. 2011;31(2):161–201.
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Matsuno RK, Lurie G, Wilkens LR, Carney ME, Henderson BE, Kolonel LN, Goodman MT. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1441–1449.
   PubMed Web of Science ®Google Scholar
• Cebola I, Peinado MA. Epigenetic deregulation of the COX pathway in cancer. Prog Lipid Res. 2012;51(4):301–313.
   PubMed Web of Science ®Google Scholar
• Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014;32(16):1677–1690.
   PubMed Web of Science ®Google Scholar
• Rigas B, Tsioulias GJ. The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther. 2015;353(1):2–8.
   PubMed Web of Science ®Google Scholar
• Cui Y, Deming-Halverson SL, Shrubsole MJ, et al. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat. 2014;146(2):439–46.
   PubMed Web of Science ®Google Scholar
• Huang XZ, Gao P, Sun JX, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26(4):589–600.
   PubMed Web of Science ®Google Scholar
• Xu J, Yin Z, Gao W, et al. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer. 2012;13(1):44–51.
   PubMed Web of Science ®Google Scholar
• Tan XL, Reid Lombardo KM, Bamlet WR, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila). 2011;4(11):1835–1841.
   PubMed Web of Science ®Google Scholar
• Dell'Atti L. Correlation between prolonged use of aspirin and prognostic risk in prostate cancer. Tumori. 2014;100(5):486–490.
   PubMed Web of Science ®Google Scholar
• Vidal AC, Howard LE, Moreira DM, et al. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res. 2015;21(4):756–762.
   PubMed Web of Science ®Google Scholar
• Duncan K, Uwimpuhwe H, Czibere A, et al. NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo. IUBMB Life. 2012;64(7):636–643.
   PubMed Web of Science ®Google Scholar
• Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012;118(19):4768–4776.
   PubMed Web of Science ®Google Scholar
• Chiou SK, Hoa N, Hodges A, et al. Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of Survivin and Aurora B kinase proteins. Apoptosis. 2014;19(9):1378–1388.
   PubMed Web of Science ®Google Scholar
• Akrami H, Aminzadeh S, Fallahi H. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015;36(5):3237–3243.
   PubMed Web of Science ®Google Scholar
• Bank A, Yu J, Zhang L. NSAIDs downregulate Bcl-X(L) and dissociate BAX and Bcl-X(L) to induce apoptosis in colon cancer cells. Nutr Cancer. 2008;60(1):98–103.
   PubMed Web of Science ®Google Scholar
• De Groot DJ, Van Der Deen M, Le TK, et al. Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007;97(8):1077–1083.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim JE, Lim do Y, et al. Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K. Cancer Prev Res (Phila). 2014;7(2):236–245.
   PubMed Web of Science ®Google Scholar
• Correia I, Arantes-Rodrigues R, Pinto-Leite R, et al. Effects of naproxen on cell proliferation and genotoxicity in MG-63 osteosarcoma cell line. J Toxicol Environ Health A. 2014;77(14-16):916–923.
   PubMed Web of Science ®Google Scholar
• Ong CK, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5(1):19–34.
   PubMedGoogle Scholar
• Culita DC, Alexandrova R, Dyakova L, et al. Evaluation of Cytotoxic and Antiproliferative Activity of Co(II), Ni(II), Cu(II) and Zn(II) Complexes with Meloxicam on Virus – Transformed Tumor Cells. Revista de Chimie. 2012;63(4):384–389.
   Web of Science ®Google Scholar
• Perzelova A, Maccova I, Mraz P, et al. Characterization of two new permanent glioma celllines 8-MG-BA and 42-MG-BA. Neoplasma. 1998;42:25–29.
   Google Scholar
• Callaway E. Deal done over HeLa cell line. Nature. 2013;500(7461):132–133.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett. 1985;24(2–3):119–124.
   PubMed Web of Science ®Google Scholar
• Saotome K, Morita H, Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxic in vitro. 1989;3(4):317–321.
   PubMed Web of Science ®Google Scholar
• Wahab SIA, Abdul AB, Alzubairi AS, et al. J Biomed Biotechnol. 2009;2009:769568. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433944/.
   Google Scholar
• Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res. 1990;122(1):86–94.
   PubMed Web of Science ®Google Scholar
• Niles AL, Moravec RA, Riss TL. Update on in vitro cytotoxicity assays for drug development. Expert Opin Drug Discov. 2008;3(6):655–669.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Bose M, Sarkar M. Spectroscopic studies of the binding of Cu(II) complexes of oxicam NSAIDs to alternating G-C and homopolymeric G-C sequences. Spectrochim Acta A Mol Biomol Spectrosc. 2014;122:690–697.
   PubMed Web of Science ®Google Scholar
• Telliez A, Furman C, Pommery N, et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem. 2006;6(3):187–208.
   PubMedGoogle Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82(1–4):85–94.
   PubMed Web of Science ®Google Scholar
• Misra S, Sharma K. COX-2 signaling and cancer: new players in old arena. Curr Drug Targets. 2014;15(3):347–359.
   PubMed Web of Science ®Google Scholar
• Bodey B, Siegel SE, Kaiser HE. Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors. In Vivo. 2006;20(4):519–525.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 2001;7(2):429–434.
   PubMed Web of Science ®Google Scholar
• Xu K, Wang L, Shu HK. COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget. 2014;5(5):1241–1252.
   PubMedGoogle Scholar
• Sharma V, Dixit D, Ghosh S, et al. COX-2 regulates the proliferation of glioma stem like cells. Neurochem Int. 2011;59(5):567–571.
   PubMed Web of Science ®Google Scholar
• Montejo C, Barciab E, Negro S, et al. Effective antiproliferative effect of Meloxicam on prostate cancer cells: development of a new controlled release. Int J Pharm. 2010;387(1–2):223–229.
   PubMed Web of Science ®Google Scholar
• Goldman AP, Williams CS, Sheng H, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 1998;19(12):2195–2199.
   PubMed Web of Science ®Google Scholar
• Dong X, Li R, Xiu P, et al. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways. PLoS One. 2014;9(3):e92864.
   PubMed Web of Science ®Google Scholar
• Naruse T, Nishida Y, Hosono K, et al. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 2006;27(3):584–592.
   PubMed Web of Science ®Google Scholar
• Iwase N, Higuchi T, Gonda T, et al. The effect of meloxicam, a selective COX-2 inhibitor, on the microvasculature of small metastatic liver tumors in rats. Jpn J Clin Oncol. 2007;37(9):673–678.
   PubMed Web of Science ®Google Scholar
• Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. 2000;20(5A):2867–2872.
   PubMed Web of Science ®Google Scholar
• Xin B, Yokoyama Y, Shigeto T, et al. Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathol Oncol Res. 2007;13(4):365–369.
   PubMed Web of Science ®Google Scholar
• Naruse T, Nishida Y, Ishiguro N. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed Pharmacother. 2007;61(6):338–346.
   PubMed Web of Science ®Google Scholar
• Hassan MH, El-Beshbishy HA, Aly H, et al. Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice. Cancer Chemother Pharmacol. 2014;74(3):559–569.
   PubMed Web of Science ®Google Scholar
• Hassan MH, Ghobara M, Abd-Allah GM. Modulator effects of meloxicam against doxorubicin-induced nephrotoxicity in mice. J Biochem Mol Toxicol. 2014;28(8):337–346.
   PubMed Web of Science ®Google Scholar
• Palayoor ST, J-Aryankalayil M, Makinde AY, et al. Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012;59(6):487–499.
   PubMed Web of Science ®Google Scholar
• Tamasi G, Casolaro M, Magnani A, et al. New platinum – oxicamcomplexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. J Inorg Biochem. 2010;104(8):799–814.
   PubMed Web of Science ®Google Scholar
• Cini R., Anti-inflammatory compounds as ligands in metal complexes as revealed in X-ray structural studies. Comments Inorg Chem. 2000;22(3-4):151–186.
   Web of Science ®Google Scholar
• Tinsley HN, Grizzle WE, Abadi A, et al. New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res. 2013;191:105–20.
   PubMedGoogle Scholar
• Ayakawa S, Shibamoto Y, Sugie C, et al. Antitumor effects of a cyclooxygenase-2 inhibitor, meloxicam, alone and in combination with radiation and/or 5-fluorouracil in cultured tumor cells. Mol Med Rep. 2009;2(4):621–625.
   Web of Science ®Google Scholar
• Roy S, Banerjee R, Sarkar M. Direct binding of Cu(II)-complexes of oxicam NSAIDs with DNA backbone. J Inorg Biochem. 2006;100(8):1320–1331.
   PubMed Web of Science ®Google Scholar
• Kardosh A, Blumenthal M, Wang WJ, et al. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther. 2004;3(1):55–62.
   PubMed Web of Science ®Google Scholar
• Sareddy GR, Geeviman K, Ramulu C, et al. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J Neurooncol. 2012;106(1):99–109.
   PubMed Web of Science ®Google Scholar
• Daugherty SE, Moore SC, Pfeiffer RM, et al. Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort. Cancer Prev Res. (Phila). 2011;4(12):2027–2034.
   PubMed Web of Science ®Google Scholar
• Karl T, Seibert N, Stöhr M, et al. Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007;245(1–2):103–111.
   PubMed Web of Science ®Google Scholar
• Dyakova L, Culia DC, Marinescu G, et al. Metal Zn(II), Cu(II), Ni(II) complexes of ursodeoxycholic acid as putative anticancer agents. Biotechnol Biotechnol Equip. 2014;28(3):543–551.
   PubMed Web of Science ®Google Scholar
• Pantcheva I, Alexandrova R, Zhivkova T, et al. In vitro activity of biometal(II) complexes of monensin against virus-induced transplantable animal tumors. Biotechnol Biotechnol Equip. 2013;27(2):3703–3708.
   Web of Science ®Google Scholar